823 results match your criteria Blood Cancer Journal[Journal]


Umbilical cord blood versus unrelated donor transplantation in adults with primary refractory or relapsed acute myeloid leukemia: a report from Eurocord, the Acute Leukemia Working Party and the Cord Blood Committee of the Cellular Therapy and Immunobiology Working Party of the EBMT.

Blood Cancer J 2019 Apr 12;9(4):46. Epub 2019 Apr 12.

EBMT Paris Study Office/CEREST-TC, Paris, France.

The role of umbilical cord blood transplantation (CBT) in acute myeloid leukemia (AML) patients with active disease at allogeneic hematopoietic cell transplantation (allo-HCT) remains poorly investigated. In this study, we compared transplantation outcomes of 2963 patients with primary refractory or relapsed AML given CBT, 10/10 HLA-matched UD, or 9/10 HLA-matched UD allo-HCT from 2004 to 2015 at EBMT-affiliated centers. Neutrophil engraftment and complete remission rates in CBT, UD 10/10, and UD 9/10 recipients were 75 and 48%, 93 and 69%, and 93 and 70%, respectively. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41408-019-0204-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6461673PMC

Current status of autologous stem cell transplantation for multiple myeloma.

Blood Cancer J 2019 Apr 8;9(4):44. Epub 2019 Apr 8.

Service d'hématologie clinique et thérapie cellulaire, Hôpital Saint-Antoine, INSERM UMRs 938 and université Sorbonne, Paris, France.

More than 30 years after its introduction, autologous stem cell transplantation (ASCT) remains the standard of care for young patients with newly diagnosed multiple myeloma. Not only did the arrival of novel agents such as immunomodulatory drugs (IMiDs), proteasome inhibitors (PI) and monoclonal antibodies not replace ASCT, instead they solidified its central role as standard of care. Novel agent use is now inarguably essential in induction, maintenance, and possibly consolidation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41408-019-0205-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6453900PMC
April 2019
1 Read

Mice with Calr mutations homologous to human CALR mutations only exhibit mild thrombocytosis.

Blood Cancer J 2019 Mar 29;9(4):42. Epub 2019 Mar 29.

Department of Gastroenterology and Hematology, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.

Calreticulin (CALR) exon 9 frameshift mutations, commonly detected in essential thrombocythemia (ET) and primary myelofibrosis patients, activate signal transducer and activator of transcription (STAT) proteins in the presence of Myeloproliferative Leukemia Virus (MPL) and induce ET in vivo. Loss of the KDEL motif, an endoplasmic reticulum retention signal, and generation of many positively charged amino acids (AAs) in the mutated C-terminus are thought to be important for disease induction. To test this hypothesis, we generated mice harboring a Calr frameshift mutation using the CRISPR/Cas9 system. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41408-019-0202-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6440999PMC
March 2019
2 Reads

Inhibition of the STAT3 target SGK1 sensitizes diffuse large B cell lymphoma cells to AKT inhibitors.

Blood Cancer J 2019 Mar 29;9(4):43. Epub 2019 Mar 29.

Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, 53726, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41408-019-0203-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6441016PMC
March 2019
1 Read

Phase I trial of isatuximab monotherapy in the treatment of refractory multiple myeloma.

Blood Cancer J 2019 Mar 29;9(4):41. Epub 2019 Mar 29.

City of Hope Cancer Center and International Myeloma Foundation, Los Angeles, CA, USA.

This phase I dose-escalation/expansion study evaluated isatuximab (anti-CD38 monoclonal antibody) monotherapy in patients with relapsed/refractory multiple myeloma (RRMM). Patients progressing on or after standard therapy received intravenous isatuximab (weekly [QW] or every 2 weeks [Q2W]). The primary objective was to determine the maximum tolerated dose (MTD) of isatuximab. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41408-019-0198-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6440961PMC
March 2019
1 Read

Types of second primary cancers influence survival in chronic lymphocytic and hairy cell leukemia patients.

Blood Cancer J 2019 Mar 26;9(4):40. Epub 2019 Mar 26.

Division of Molecular Genetic Epidemiology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 580, D-69120, Heidelberg, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41408-019-0201-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6435725PMC
March 2019
1 Read

Deciphering the chronology of copy number alterations in Multiple Myeloma.

Blood Cancer J 2019 Mar 26;9(4):39. Epub 2019 Mar 26.

Department of Data Sciences, Dana Farber Cancer Institute, Boston, MA, 02215, USA.

Multiple myeloma (MM) and its precursor condition MGUS are characterized by chromosomal aberrations. Here, we comprehensively characterize the order of occurrence of these complex genomic events underlying MM development using 500 MGUS, and MM samples. We identify hyperdiploid MM (HMM) and non-HMM as genomically distinct entities with different evolution of the copy number alterations. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41408-019-0199-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6435669PMC
March 2019
1 Read

Treatment of patients with multiple myeloma progressing on frontline-therapy with lenalidomide.

Blood Cancer J 2019 Mar 20;9(4):38. Epub 2019 Mar 20.

University Hospital, Salamanca, Spain.

Over the last years, there has been great progress in the treatment of multiple myeloma with many new agents and combinations having been approved and being now routinely incorporated into treatment strategies. As a result, patients are experiencing benefits in terms of survival and better tolerance. However, the multitude of treatment options also presents a challenge to select the best options tailored to the specific patient situation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41408-019-0200-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6426995PMC

Antibody-drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study.

Blood Cancer J 2019 Mar 20;9(4):37. Epub 2019 Mar 20.

Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.

Interim analyses of a phase I study with GSK2857916, an antibody-drug conjugate against B cell maturation antigen, have previously reported a 60% overall response and 7.9 months progression-free survival in relapsed/refractory multiple myeloma (MM). We provide updated safety and efficacy results of the BMA117159 trial following an additional 14 months' follow-up. Read More

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41408-019-0196-6
Publisher Site
http://dx.doi.org/10.1038/s41408-019-0196-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6426965PMC
March 2019
2 Reads

Predicting long-term disease control in transplant-ineligible patients with multiple myeloma: impact of an MGUS-like signature.

Blood Cancer J 2019 Mar 18;9(4):36. Epub 2019 Mar 18.

Clínica Universidad de Navarra, CIMA, IDISNA, CIBERONC, Pamplona, Spain.

Disease control at 5 years would be a desirable endpoint for elderly multiple myeloma (MM) patients, but biomarkers predicting this are not defined. Therefore, to gain further insights in this endpoint, a population of 498 newly diagnosed transplant-ineligible patients enrolled in two Spanish trials (GEM2005MAS65 and GEM2010MAS65), has been analyzed. Among the 435 patients included in this post-hoc study, 18. Read More

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41408-019-0176-x
Publisher Site
http://dx.doi.org/10.1038/s41408-019-0176-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6423121PMC
March 2019
5 Reads

CBFβ-MYH11 interferes with megakaryocyte differentiation via modulating a gene program that includes GATA2 and KLF1.

Blood Cancer J 2019 Mar 8;9(3):33. Epub 2019 Mar 8.

Department of Molecular Biology, Faculty of Science, Radboud Institute for Molecular Life Sciences, Radboud University Nijmegen, 6525 GA, Nijmegen, The Netherlands.

The inv(16) acute myeloid leukemia-associated CBFβ-MYH11 fusion is proposed to block normal myeloid differentiation, but whether this subtype of leukemia cells is poised for a unique cell lineage remains unclear. Here, we surveyed the functional consequences of CBFβ-MYH11 in primary inv(16) patient blasts, upon expression during hematopoietic differentiation in vitro and upon knockdown in cell lines by multi-omics profiling. Our results reveal that primary inv(16) AML cells share common transcriptomic signatures and epigenetic determiners with megakaryocytes and erythrocytes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41408-019-0194-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6408575PMC

Natural history of multiple myeloma with de novo del(17p).

Blood Cancer J 2019 Mar 7;9(3):32. Epub 2019 Mar 7.

Division of Hematology, Mayo Clinic, Rochester, MN, USA.

We compared the outcomes of 310 patients with newly diagnosed multiple myeloma with del(17p) detected by FISH to patients with high-risk translocations (HRT) (n = 79) and standard-risk (SR) cytogenetics (n = 541). The median progression-free survival (PFS) following initial therapy for the three groups was 21.1, 22, and 30. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41408-019-0191-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6405846PMC
March 2019
1 Read

Graft-versus-MDS effect after unrelated cord blood transplantation: a retrospective analysis of 752 patients registered at the Japanese Data Center for Hematopoietic Cell Transplantation.

Blood Cancer J 2019 Mar 6;9(3):31. Epub 2019 Mar 6.

Department of Hematology, Nagasaki University Hospital, Nagasaki, Japan.

Allogeneic hematopoietic stem cell transplantation is the sole curative therapy for myelodysplastic syndrome (MDS). However, there is concern regarding graft failure and relapse in patients who undergo cord blood transplantation (CBT). We conducted a retrospective study of the CBT outcomes in MDS patients using the Japanese Data Center for Hematopoietic Cell Transplantation database. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41408-019-0192-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6403210PMC
March 2019
1 Read

Two types of amyloidosis presenting in a single patient: a case series.

Blood Cancer J 2019 Mar 5;9(3):30. Epub 2019 Mar 5.

Division of Hematology, Department of Internal Medicine, Mayo Clinic Rochester, Rochester, MN, USA.

The amyloidoses are a group of disorders with overlapping clinical presentations, characterized by aggregation and tissue deposition of misfolded proteins. The nature and source of the amyloidogenic protein determines therapy, therefore correct subtyping is critical to patient management. We report the clinicopathologic features of nine patients diagnosed with two amyloid types confirmed by liquid chromatography-coupled tandem mass spectrometry. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41408-019-0193-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6401104PMC
March 2019
1 Read

World Health Organization class-independent risk categorization in mastocytosis.

Blood Cancer J 2019 Mar 4;9(3):29. Epub 2019 Mar 4.

Divisions of Hematology, Departments of Internal Medicine and Laboratory Medicine, Mayo Clinic, Rochester, MN, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41408-019-0189-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6399221PMC
March 2019
1 Read

Correction: High expression of HMGA2 independently predicts poor clinical outcomes in acute myeloid leukemia.

Blood Cancer J 2019 Feb 28;9(3):28. Epub 2019 Feb 28.

The Quebec Leukemia Cell Bank, Research Centre, Maisonneuve-Rosemont Hospital, Montréal, Canada.

Since the publication of the original article the authors noticed the the affiliation details for Paresh Vyas are incorrect. The correct affiliation details for this author are given below. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41408-019-0190-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6395678PMC
February 2019
2 Reads
2.884 Impact Factor

Management of cardiovascular risk in patients with multiple myeloma.

Blood Cancer J 2019 Feb 26;9(3):26. Epub 2019 Feb 26.

Hematology Service, University Hospital Salamanca, Casa del Bedel, Cardenal Pla y Deniel, 22, Planta Baja, Salamanca, 37008, Spain.

Multiple myeloma (MM) is a plasma cell malignancy that accounts for 10% of hematological cancers. It predominantly affects elderly people; median age at diagnosis is 70 years. Consequently, many patients with MM have cardiovascular comorbidities or risk factors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41408-019-0183-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6391463PMC
February 2019
1 Read

Elevated IgM and abnormal free light chain ratio are increased in relatives from high-risk chronic lymphocytic leukemia pedigrees.

Blood Cancer J 2019 Feb 26;9(3):25. Epub 2019 Feb 26.

University of Utah School of Medicine, Salt Lake City, UT, 84112, USA.

Abnormal serum immunoglobulin (Ig) free light chains (FLC) are established biomarkers of early disease in multiple B-cell lymphoid malignancies, including chronic lymphocytic leukemia (CLL). Heavy chains have also been shown to be biomarkers in plasma cell disorders. An unanswered question is whether these Ig biomarkers are heritable, i. Read More

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41408-019-0186-8
Publisher Site
http://dx.doi.org/10.1038/s41408-019-0186-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6391432PMC
February 2019
7 Reads

The effect of CRM1 inhibition on human non-Hodgkin lymphoma cells.

Blood Cancer J 2019 Feb 26;9(3):24. Epub 2019 Feb 26.

Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41408-019-0188-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6391437PMC
February 2019

The role of cement augmentation with percutaneous vertebroplasty and balloon kyphoplasty for the treatment of vertebral compression fractures in multiple myeloma: a consensus statement from the International Myeloma Working Group (IMWG).

Blood Cancer J 2019 Feb 26;9(3):27. Epub 2019 Feb 26.

University of Athens School of Medicine, Athens, Greece.

Multiple myeloma (MM) represents approximately 15% of haematological malignancies and most of the patients present with bone involvement. Focal or diffuse spinal osteolysis may result in significant morbidity by causing painful progressive vertebral compression fractures (VCFs) and deformities. Advances in the systemic treatment of myeloma have achieved high response rates and prolonged the survival significantly. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41408-019-0187-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6391474PMC
February 2019
3 Reads

Health-related quality of life in the ENDEAVOR study: carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed/refractory multiple myeloma.

Blood Cancer J 2019 Feb 22;9(3):23. Epub 2019 Feb 22.

Universitatsklinikum Tubingen, Tubingen, Germany.

We examined effects of carfilzomib-dexamethasone (Kd56) versus bortezomib-dexamethasone (Vd) on health-related quality of life (HR-QoL) in relapsed/refractory multiple myeloma (MM) patients from the ENDEAVOR study. HR-QoL was assessed by the European Organisation for Research and Treatment of Cancer QoL Questionnaire (QLQ-C30), MM-specific module (QLQ-MY20), and Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (FACT-GOG-Ntx) "Additional Concerns" neurotoxicity subscale. The QLQ-C30 Global Health Status (GHS)/QoL scale and seven prespecified subscales were compared between groups using mixed model for repeated measures. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41408-019-0181-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6386751PMC
February 2019
7 Reads

Reverse signaling via PD-L1 supports malignant cell growth and survival in classical Hodgkin lymphoma.

Blood Cancer J 2019 Feb 19;9(3):22. Epub 2019 Feb 19.

Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN, USA.

Treatment with programmed death-1 (PD-1) blocking antibodies results in high overall response rates in refractory and relapsed classical Hodgkin lymphoma (cHL) patients, indicating that PD-1/PD-1 ligand interactions are integral to progression of this disease. Given the genetically driven increased PD-L1/2 expression in HL, we hypothesized that reverse signaling through PD-1 ligands may be a potential mechanism contributing to the growth and survival of Hodgkin Reed-Sternberg (HRS) cells in cHL. Our data show that engagement of PD-L1 using an agonistic monoclonal antibody increases cell survival and proliferation and reduces apoptosis in HL cell lines. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41408-019-0185-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6381098PMC
February 2019
1 Read

Expanding the repertoire of miRNAs and miRNA-offset RNAs expressed in multiple myeloma by small RNA deep sequencing.

Blood Cancer J 2019 Feb 19;9(3):21. Epub 2019 Feb 19.

Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.

Microarray analysis of the multiple myeloma (MM) miRNome has unraveled the differential expression of miRNAs in cytogenetic subgroups, their involvement in the tumor biology and their effectiveness in prognostic models. Herein, the small RNA transcriptional landscape in MM has been investigated exploiting the possibilities offered by small RNA-seq, including accurate quantification of known mature species, discovery and characterization of isomiRs, and miRNA-offset RNAs (moRNAs). Matched small RNA-seq and miRNA GeneChip microarray expression profiles were obtained in a representative panel of 30 primary MM tumors, fully characterized for genomic aberrations and mutations. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41408-019-0184-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6381125PMC
February 2019
1 Read

Identification of lenalidomide resistance pathways in myeloma and targeted resensitization using cereblon replacement, inhibition of STAT3 or targeting of IRF4.

Blood Cancer J 2019 Feb 11;9(2):19. Epub 2019 Feb 11.

Division of Hematology, Mayo Clinic, Scottsdale, AZ, USA.

To understand immunomodulatory drug (IMiD) resistance in multiple myeloma (MM), we created isogenic human multiple myeloma cell lines (HMCLs) sensitive and resistant to lenalidomide, respectively. Four HMCLs were demonstrated to be resistant to all IMiDs including lenalidomide, pomalidomide, and CC-220, but not to Bortezomib. In three HMLCs (MM. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41408-019-0173-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6370766PMC
February 2019
4 Reads

Validation of the Mayo alliance prognostic system for mastocytosis.

Blood Cancer J 2019 Feb 11;9(2):18. Epub 2019 Feb 11.

CRIMM, Centro di Ricerca e Innovazione per le Malattie Mieloproliferative, Azienda Ospedaliera Universitaria Careggi, Dipartimento di Medicina Sperimentale e Clinica, Università degli Studi, Firenze, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41408-019-0179-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6370807PMC
February 2019

Phase I study of the anti-FcRH5 antibody-drug conjugate DFRF4539A in relapsed or refractory multiple myeloma.

Blood Cancer J 2019 Feb 4;9(2):17. Epub 2019 Feb 4.

Sarah Cannon Research Institute, Nashville, TN, USA.

FcRH5 is a cell surface marker enriched on malignant plasma cells when compared to other hematologic malignancies and normal tissues. DFRF4539A is an anti-FcRH5 antibody-drug conjugated to monomethyl auristatin E (MMAE), a potent anti-mitotic agent. This phase I study assessed safety, tolerability, maximum tolerated dose (MTD), anti-tumor activity, and pharmacokinetics of DFRF4539A in patients with relapsed/refractory multiple myeloma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41408-019-0178-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6362066PMC
February 2019
6 Reads
2.884 Impact Factor

Molecular underpinnings of clinical disparity patterns in African American vs. Caucasian American multiple myeloma patients.

Blood Cancer J 2019 Feb 4;9(2):15. Epub 2019 Feb 4.

Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York City, NY, USA.

Caucasian Americans (CA) compared with African Americans (AA) have a twofold increased incidence of multiple myeloma (MM) and have an earlier age of diagnosis. However, there is sparse information regarding underlying biological differences across racial/ethnic groups. We characterized genetic alterations using a targeted next-generation sequencing assay called myTYPE, developed at MSKCC, allowing capture of somatic mutations, IgH translocations, gains/losses, and hyperdiploidy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41408-019-0177-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6361959PMC
February 2019
1 Read

Cereblon-binding proteins expression levels correlate with hyperdiploidy in newly diagnosed multiple myeloma patients.

Blood Cancer J 2019 Jan 29;9(2):13. Epub 2019 Jan 29.

Department of Hematology, Oncology and Rheumatology, Heidelberg University, Heidelberg, Germany.

Immunomodulatory drugs (IMIDs) are very effective in the treatment of multiple myeloma (MM). The description of their cereblon-mediated mechanism of action was a hallmark in MM research. Although the importance of IMID-induced degradation of cereblon-binding proteins is well described in vitro, the prognostic value of their expression levels in MM cells is less clear. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41408-019-0174-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6351644PMC
January 2019
1 Read

CDC37 as a novel target for the treatment of NPM1-ALK expressing anaplastic large cell lymphomas.

Blood Cancer J 2019 Jan 29;9(2):14. Epub 2019 Jan 29.

Division of Hematologic Malignancies and Cellular Therapeutics, Department of Internal Medicine, University of Kansas Medical Center, Kansas City, KS, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41408-019-0171-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6351628PMC
January 2019
4 Reads

Leukemic transformation among 1306 patients with primary myelofibrosis: risk factors and development of a predictive model.

Blood Cancer J 2019 Jan 25;9(2):12. Epub 2019 Jan 25.

Departments of Divisions of Hematology, Mayo Clinic, Rochester, MN, USA.

Among 1306 patients with primary myelofibrosis (PMF), we sought to identify risk factors that predicted leukemic transformation (LT) in the first 5 years of disease and also over the course of the disease. 149 (11%) LT were documented; patients who subsequently developed LT (n = 149), compared to those who remained in chronic phase disease (n = 1,157), were more likely to be males (p = 0.02) and display higher circulating blasts (p = 0. Read More

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41408-019-0175-y
Publisher Site
http://dx.doi.org/10.1038/s41408-019-0175-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6347609PMC
January 2019
19 Reads

The journey to CAR T cell therapy: the pediatric and young adult experience with relapsed or refractory B-ALL.

Blood Cancer J 2019 Jan 22;9(2):10. Epub 2019 Jan 22.

Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, PA, USA.

Outcomes of pediatric and young adult patients diagnosed with acute lymphoblastic leukemia (ALL) have improved significantly in the past few decades. Treatment advances have provided 5-year survival rates ranging from 78 to 91% depending on the age at diagnosis. However, approximately 2-3% of patients will present with refractory disease that is unresponsive to chemotherapy, and 10-15% of patients will relapse. Read More

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41408-018-0164-6
Publisher Site
http://dx.doi.org/10.1038/s41408-018-0164-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6342933PMC
January 2019
8 Reads

High frequencies of circulating memory T cells specific for calreticulin exon 9 mutations in healthy individuals.

Blood Cancer J 2019 Jan 17;9(2). Epub 2019 Jan 17.

Center for Cancer Immune Therapy, Department of Hematology, Copenhagen University Hospital Herlev, Herlev, Denmark.

Mutations in exon 9 of the calreticulin gene (CALR) frequently occur in patients with chronic myeloproliferative neoplasms (MPN). Patients exhibit spontaneous cellular immune responses to epitopes derived from the mutant CALR C-terminus, and CALR-mutant-specific T cells recognize autologous CALR-mutant malignant cells. This study investigated whether CALR-mutant-specific T cells occur naturally in CALRwt MPN-patients and in healthy individuals. Read More

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41408-018-0166-4
Publisher Site
http://dx.doi.org/10.1038/s41408-018-0166-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6336769PMC
January 2019
14 Reads

Late relapse in acute myeloid leukemia (AML): clonal evolution or therapy-related leukemia?

Blood Cancer J 2019 Jan 16;9(2). Epub 2019 Jan 16.

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Late relapse, defined as relapse arising after at least 5 years of remission, is rare and occurs in 1-3% of patients with acute myeloid leukemia (AML). The underlying mechanisms of late relapse remain poorly understood. We identified patients with AML who achieved remission with standard induction chemotherapy and relapsed after at least five years of remission (n = 15). Read More

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41408-019-0170-3
Publisher Site
http://dx.doi.org/10.1038/s41408-019-0170-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6335405PMC
January 2019
17 Reads
2.884 Impact Factor

Humanized anti-CD123 antibody facilitates NK cell antibody-dependent cell-mediated cytotoxicity (ADCC) of Hodgkin lymphoma targets via ARF6/PLD-1.

Blood Cancer J 2019 Jan 15;9(2). Epub 2019 Jan 15.

Cell Therapy Program, Princess Margaret Cancer Centre, Toronto, ON, Canada.

CD123 (IL-3Rα) is frequently expressed by malignant Hodgkin lymphoma (HL) cells. Naked monoclonal antibodies (mAb) against HL lack clinical benefit, partially due to absence of natural killer (NK) cells in the tumor microenvironment. Here we show that the combination of a fully humanized anti-CD123 mAb (CSL362) and high-affinity Fcγ-receptor NK-92 cells (haNK) effectively target and kill HL cells in vitro. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41408-018-0168-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6333842PMC
January 2019
2 Reads

The ALK inhibitor AZD3463 effectively inhibits growth of sorafenib-resistant acute myeloid leukemia.

Blood Cancer J 2019 Jan 15;9(2). Epub 2019 Jan 15.

Division of Translational Cancer Research, Department of Laboratory Medicine, Lund University, Lund, Sweden.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41408-018-0169-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6333797PMC
January 2019
2 Reads

Superior efficacy of cotreatment with BET protein inhibitor and BCL2 or MCL1 inhibitor against AML blast progenitor cells.

Blood Cancer J 2019 Jan 15;9(2). Epub 2019 Jan 15.

The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.

First-generation bromodomain extra-terminal protein (BETP) inhibitors (BETi) (e.g., OTX015) that disrupt binding of BETP BRD4 to chromatin transcriptionally attenuate AML-relevant progrowth and prosurvival oncoproteins. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41408-018-0165-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6333829PMC
January 2019
1 Read

Combining carfilzomib and panobinostat to treat relapsed/refractory multiple myeloma: results of a Multiple Myeloma Research Consortium Phase I Study.

Blood Cancer J 2019 01 4;9(1). Epub 2019 Jan 4.

Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA, USA.

Proteasome (PIs) and hystone deacetylase inhibitors (HDACis) have previously shown synergistic activity in the treatment of relapesed/refractory multiple myeloma (RRMM) patients. In this phase 1 study, we combined carfilzomib, a second generation PI, with panobinostat, a HDACi, to determine the maximum tolerated dose (MTD) of the combination (CarPan) and assess safety and efficacy among RRMM patients. Thirty-two patients (median of 4 prior lines of therapy) were enrolled. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41408-018-0154-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6320362PMC
January 2019
11 Reads

Molecular signatures of multiple myeloma progression through single cell RNA-Seq.

Blood Cancer J 2019 01 3;9(1). Epub 2019 Jan 3.

Genome Analysis Core, Medical Genome Facility, Center for Individualized Medicine, Mayo Clinic, Rochester, MN, USA.

We used single cell RNA-Seq to examine molecular heterogeneity in multiple myeloma (MM) in 597 CD138 positive cells from bone marrow aspirates of 15 patients at different stages of disease progression. 790 genes were selected by coefficient of variation (CV) method and organized cells into four groups (L1-L4) using unsupervised clustering. Plasma cells from each patient clustered into at least two groups based on gene expression signature. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41408-018-0160-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6318319PMC
January 2019
1 Read

Genetic correlation between multiple myeloma and chronic lymphocytic leukaemia provides evidence for shared aetiology.

Blood Cancer J 2018 12 21;9(1). Epub 2018 Dec 21.

Division of Genetics and Epidemiology, The Institute of Cancer Research, London, SW7 3RP, UK.

The clustering of different types of B-cell malignancies in families raises the possibility of shared aetiology. To examine this, we performed cross-trait linkage disequilibrium (LD)-score regression of multiple myeloma (MM) and chronic lymphocytic leukaemia (CLL) genome-wide association study (GWAS) data sets, totalling 11,734 cases and 29,468 controls. A significant genetic correlation between these two B-cell malignancies was shown (R = 0. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41408-018-0162-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6315026PMC
December 2018
16 Reads
2.884 Impact Factor

Overall survival of transplant eligible patients with newly diagnosed multiple myeloma: comparative effectiveness analysis of modern induction regimens on outcome.

Blood Cancer J 2018 12 11;8(12):125. Epub 2018 Dec 11.

Division of Hematology, Mayo Clinic, Rochester, MN, USA.

Overall survival (OS) of multiple myeloma has improved remarkably over time, with the recent Intergroupe Francophone du Myelome (IFM) 2009 randomized trial reporting a 4-year OS rate of approximately 82% in patients receiving modern therapy. However, survival estimates from clinical trials may overestimate outcomes seen in clinical practice even with the adjustment for age and other key characteristics. The purpose of this study was to determine the OS of myeloma patients seen in routine clinical practice who resembled the cohort studied in the IFM 2009 trial. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41408-018-0163-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6289963PMC
December 2018
2 Reads

Feasibility of treatment discontinuation in chronic myeloid leukemia in clinical practice: results from a nationwide series of 236 patients.

Blood Cancer J 2018 12 2;8(10):91. Epub 2018 Dec 2.

Hematology Department, Hospital Universitario La Princesa, Madrid, Spain.

Over half of chronic myeloid leukemia (CML) patients in deep molecular response do not lose the major molecular response (MMR) after stopping treatment with tyrosine kinase inhibitors (TKI). This strategy is safe in clinical trials, but its applicability in the real-life setting remains unsettled. We describe the outcomes after TKI discontinuation in a nationwide series of 236 CML patients. Read More

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41408-018-0125-0
Publisher Site
http://dx.doi.org/10.1038/s41408-018-0125-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6275158PMC
December 2018
25 Reads

Different effect of hydroxyurea and phlebotomy on prevention of arterial and venous thrombosis in Polycythemia Vera.

Blood Cancer J 2018 11 26;8(12):124. Epub 2018 Nov 26.

Department of Experimental and Clinical Medicine, Center of Research and Innovation of Myeloproliferative neoplasms (CRIMM), AOU Careggi, University of Florence, Florence, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41408-018-0161-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6255832PMC
November 2018
3 Reads

Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma - an IMWG Research Project.

Blood Cancer J 2018 11 23;8(12):123. Epub 2018 Nov 23.

service d'Hematologie, CHU de Nantes, Nantes, France.

Purpose: multiple myeloma is considered an incurable hematologic cancer but a subset of patients can achieve long-term remissions and survival. The present study examines the clinical features of long-term survival as it correlates to depth of disease response.

Patients & Methods: this was a multi-institutional, international, retrospective analysis of high-dose melphalan-autologous stem cell transplant (HDM-ASCT) eligible MM patients included in clinical trials. Read More

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41408-018-0155-7
Publisher Site
http://dx.doi.org/10.1038/s41408-018-0155-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6251924PMC
November 2018
21 Reads